IOVANCE BIOTHERAPEUTICS, INC. Amortization of Debt Issuance Costs
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Amortization of Debt Issuance Costs of $2.87 million for the 78-month period ending 2014-03-31, per its 10-Q filed 2014-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2014-05-14
- IOVANCE BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2012-12-31 was $875.00K.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2012-09-30 was $515.27K.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2012 was $1.39M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 69 month | Amortization of Debt Issuance Costs 72 month | Amortization of Debt Issuance Costs 78 month |
|---|---|---|---|---|---|---|---|
| 2014-03-31 | $2.87M 10-Q · filed 2014-05-14 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2014-03-28 | $2.87M 10-K · filed 2014-03-28 | |||||
| 2013-09-30 | $0.00 derived: 10-Q 72 month − 10-Q 69 month · filed 2013-11-14 | $2.87M 10-Q · filed 2013-11-14 | |||||
| 2013-06-30 | $2.87M 10-Q · filed 2013-10-23 | ||||||
| 2012-12-31 | $875.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $1.39M derived: sum of 2 quarters · filed 2014-03-28 | $1.39M 10-K · filed 2014-03-28 | ||||
| 2012-09-30 | $515.27K 10-Q · filed 2013-11-14 | $515.27K 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |